A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

Abstract Background Breast cancer remains a leading cause of cancer death worldwide. There is evidence that immunotherapy may play a role in the eradication of residual disease. Peptide vaccines for immunotherapy are capable of durable immune memory, but vaccines alone have shown sparse clinical act...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Patrick M. Dillon, Gina R. Petroni, Mark E. Smolkin, David R. Brenin, Kimberly A. Chianese-Bullock, Kelly T. Smith, Walter C. Olson, Ibrahim S. Fanous, Carmel J. Nail, Christiana M. Brenin, Emily H. Hall, Craig L. Slingluff
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMJ Publishing Group 2017-11-01
Schriftenreihe:	Journal for ImmunoTherapy of Cancer
Schlagworte:	Breast cancer immunotherapy cancer vaccine cytotoxic T-cell lymphocyte response peptide poly-ICLC
Online-Zugang:	http://link.springer.com/article/10.1186/s40425-017-0295-5
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!